诚意药业：拓展海洋生物制药产品线，如高纯度EPA

Core Viewpoint - The company is focusing on enhancing its research and development (R&D) efforts, particularly in marine biomedicine, to drive future growth and expand its product offerings in various therapeutic areas [1][2]. Group 1: R&D and Product Development - The company plans to increase its R&D expenses for the full year 2025, despite a decrease in the first half of the year due to payment schedules for certain projects [1]. - The company has over 30 products in development, focusing on marine drugs, geriatric medications, anti-tumor drugs, traditional Chinese medicine, anti-infective drugs, digestive system treatments, and the broader health industry [1]. - The company aims to leverage its advantages in marine biomedicine to develop and industrialize marine drugs, integrating existing resources and expanding its product line with high-purity EPA and other marine-derived drugs [1]. Group 2: Market Position and Product Offerings - The company is a leading manufacturer of glucosamine hydrochloride in China, establishing a competitive advantage across the entire industry chain [2]. - The main product, glucosamine hydrochloride capsules, is available in multiple specifications (0.24g, 0.48g, 0.75g) to meet diverse patient needs [2]. - As of May 2025, the company has completed contract renewals for centralized procurement in 30 provincial regions across the country, continuously expanding its market share [2].